Among a handful of Indian pharma companies working in the area of biologics

First and only listed ‘pure play’ biopharmaceuticals company in India

Globally recognised biopharmaceuticals enterprise with a unique business model that straddles both products and services

Extensive experience and demonstrated expertise in taking two novel biologics and five biosimilars from ‘lab to market’

Diversified portfolio of biosimilar insulin analogs and antibodies in advanced stages of development

400-member strong scientific team, including MDs, PhDs and Masters degree holders, drawn from within India and global biopharma organisations

In-house expertise across the drug value chain; pipeline includes proprietary and partnered programs

Incisive intellectual property strategy recognised by several national and international awards

Experience of multiple global regulatory filings in insulins, biosimilar antibodies and complex generic formulations